"For all intents and purposes, the drug industry is not pursuing research into new antibiotics. It is simply too expensive relative to possible earnings, and there is more money in drugs to treat chronic diseases such as diabetes. Therefore, the bacteria are winning the race – resistance increases and treatment options are scarce. Research will have to find new paths and natural substances are one of them," emphasises Jes Gitz Holler.